706820-76-0Relevant articles and documents
Efforts toward oral bioavailability in factor VIIa inhibitors
Vijaykumar, Dange,Rai, Roopa,Shaghafi, Michael,Ton, Tony,Torkelson, Steve,Leahy, Ellen M.,Riggs, Jennifer R.,Hu, Huiyong,Sprengeler, Paul A.,Shrader, William D.,O'Bryan, Colin,Cabuslay, Ronnell,Sanford, Ellen,Gjerstadt, Erik,Liu, Liang,Sukbuntherng, Juthamas,Young, Wendy B.
, p. 3829 - 3832 (2006)
Efforts toward developing orally bioavailable factor VIIa inhibitors starting from parenteral lead compound 1 are described. SAR resulted in improved physicochemical properties, leading to enhanced oral absorption in rat.
2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS
-
Page/Page column 26, (2010/02/07)
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.